login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First patient enrolled in REPRISE II trial to evaluate the safety and performance of the Lotus Valve System


Thursday, 11 Oct 2012 11:23

On 10 October 2012, Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease.

This international, multicentre study includes 15 sites in Australia, France, Germany and the UK. According to Boston Scientific, the Lotus Valve System is the first transcatheter aortic valve implantation (TAVI) device of its kind that is designed to minimise aortic regurgitation. The device is both fully repositionable and retrievable prior to release, offering predictable and precise placement. The results of the REPRISE II trial are expected to be used to support CE mark and other international regulatory approvals.

“We were encouraged by the promising results of the REPRISE I clinical trial completed earlier this year and we are therefore very confident about evaluating the safety and performance of the Lotus Valve in a larger patient cohort,” said Ian Meredith, director of Monash Heart, at Monash Medical Centre in Melbourne, Australia, and the principal investigator of the REPRISE II trial. “The Lotus Valve has a number of important features which address some of the limitations observed with the first generation devices. The ease of use, predictable and precise positioning, and the ability to fully reposition and retrieve the Lotus Valve offer the operator considerable reassurance and control. These features, along with the minimised risk of paravalvular leakage, may lead to improved clinical outcomes.”

The Lotus Valve System is a differentiated second-generation TAVI technology, which consists of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system used for guidance and percutaneous placement of the valve. The low-profile delivery system and introducer sheath are designed to enable predictable and precise placement, as well as bidirectional atraumatic repositioning and retrieval at any time prior to release of the aortic valve implant. The device also employs a unique Adaptive Seal feature designed to minimise the incidence of paravalvular regurgitation, which has proven to be a predictor of mortality.

Current study enrolment requires that patients have severe calcified aortic stenosis, are aged 70 years or older and are considered to be at high surgical risk, defined as an STS (Society of Thoracic Surgeons) mortality score >8 or the consensus opinion of the Heart Team. The REPRISE II study is designed to study two valve sizes, 23mm and 27mm, and have a five-year follow-up. Beyond that, it will assess for other endpoints recommended by the Valve Academic Research Consortium (VARC) and regulatory agencies. Study enrolment is expected to be completed in the first half of 2013.

“There is a high need for continued evolution of device technology to treat people with severe aortic valve disease,” said Keith D Dawkins, global chief medical officer for Boston Scientific. “We are looking forward to advancing the Boston Scientific valve program with REPRISE II, as we believe the Lotus Valve System is a unique technology that will offer interventional cardiologists greater precision and control in deployment which, in effect, may simplify the implantation procedure and lead to improved patient outcomes.”

The Lotus Valve System is an investigational device, limited by applicable law to investigational use and not available for sale. The device was developed by Sadra Medical, which Boston Scientific acquired in 2011.




Add New Comment

Related Items


Most popular


Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension
Wednesday, 06 Jan 2016
The MobiusHD minimally invasive system from Vascular Dynamics has been granted CE mark approval for the treatment of resistant hypertension. Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension

Orsiro may provide benefit over Xience for STEMI patients
Thursday, 07 Jan 2016
A pre-specified substudy of BIOSCIENCE, published in EuroIntervention, has found that Orsiro is associated with a significantly lower rate of target lesion failure than is Xience in STEMI patients at ... Orsiro may provide benefit over Xience for STEMI patients

Monday, 11 Jan 2016
Vivasure Medical has been granted CE mark approval for its fully bioabsorbable percutaneous vascular closure device for large-bore femoral arteriotomies. Vivasure granted CE mark for world’s first fully bioabsorbable percutaneous closure device for large-bore transcatheter

Features


Building the ideal heart team for transcatheter mitral valve interventions
Monday, 08 Feb 2016
In this commentary, Vinayak Bapat outlines transcatheter mitral valve interventions and reviews which specialists should comprise the optimal heart team for such procedures. Building the ideal heart team for transcatheter mitral valve interventions

Training is the key to wider adoption of the transradial approach for PCI in the USA
Monday, 25 Jan 2016
This commentary explores why the USA, despite the data supporting the transradial approach, has been more reluctant than other countries to adopt the approach. Training is the key to wider adoption of the transradial approach for PCI in the USA

Profiles


Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions